Literature DB >> 24525230

Wild-type RAS: keeping mutant RAS in CHK.

Theonie Anastassiadis1, Eric J Brown2.   

Abstract

Mutant RAS-driven tumorigenesis was thought for decades to arise independently of wild-type RAS isoforms, but recent evidence indicates wild-type isoforms are involved. In this issue of Cancer Cell, Grabocka and colleagues report how the loss of wild-type RAS alters oncogenic signaling and dampens the DNA-damage response, thereby affecting tumor progression and chemosensitivity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24525230      PMCID： PMC4050974          DOI： 10.1016/j.ccr.2014.01.029

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  10 in total

1.  Inhibition of Chk1 by activated PKB/Akt.

Authors:  Frank W King; Jennifer Skeen; Nissim Hay; Emma Shtivelman
Journal:  Cell Cycle       Date:  2004-05-31       Impact factor: 4.534

2.  Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.

Authors:  Oren Gilad; Barzin Y Nabet; Ryan L Ragland; David W Schoppy; Kevin D Smith; Amy C Durham; Eric J Brown
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

3.  Wildtype Kras2 can inhibit lung carcinogenesis in mice.

Authors:  Z Zhang; Y Wang; H G Vikis; L Johnson; G Liu; J Li; M W Anderson; R C Sills; H L Hong; T R Devereux; T Jacks; K L Guan; M You
Journal:  Nat Genet       Date:  2001-09       Impact factor: 38.330

4.  Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

Authors:  David Matallanas; David Romano; Fahd Al-Mulla; Eric O'Neill; Waleed Al-Ali; Piero Crespo; Brendan Doyle; Colin Nixon; Owen Sansom; Matthias Drosten; Mariano Barbacid; Walter Kolch
Journal:  Mol Cell       Date:  2011-12-23       Impact factor: 17.970

Review 5.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

6.  Tumour maintenance is mediated by eNOS.

Authors:  Kian-Huat Lim; Brooke B Ancrile; David F Kashatus; Christopher M Counter
Journal:  Nature       Date:  2008-03-16       Impact factor: 49.962

7.  Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function.

Authors:  D C Huang; C J Marshall; J F Hancock
Journal:  Mol Cell Biol       Date:  1993-04       Impact factor: 4.272

8.  Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling.

Authors:  Amy Young; David Lou; Frank McCormick
Journal:  Cancer Discov       Date:  2012-10-25       Impact factor: 39.397

9.  RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance.

Authors:  H Ray-David; Y Romeo; G Lavoie; P Déléris; J Tcherkezian; J A Galan; P P Roux
Journal:  Oncogene       Date:  2012-10-29       Impact factor: 9.867

Review 10.  An oncogene-induced DNA damage model for cancer development.

Authors:  Thanos D Halazonetis; Vassilis G Gorgoulis; Jiri Bartek
Journal:  Science       Date:  2008-03-07       Impact factor: 47.728
  10 in total
  1 in total

1.  Oncogenic KRAS drives radioresistance through upregulation of NRF2-53BP1-mediated non-homologous end-joining repair.

Authors:  Linlin Yang; Changxian Shen; Adriana Estrada-Bernal; Ryan Robb; Moumita Chatterjee; Nikhil Sebastian; Amy Webb; Xiaokui Mo; Wei Chen; Sunil Krishnan; Terence M Williams
Journal:  Nucleic Acids Res       Date:  2021-11-08       Impact factor: 16.971
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.